Nafithromycin, developed by Wockhardt with support from BIRAC, is India's first indigenously produced antibiotic targeting antimicrobial resistance (AMR). It is designed to treat Community-Acquired Bacterial Pneumonia (CABP) and is ten times more effective than azithromycin. This significant breakthrough follows 14 years of research and aims to address the global health crisis of AMR, which is responsible for millions of deaths annually. The drug awaits final approval from the Central Drugs Standard Control Organization (CDSCO) for public use.
This Question is Also Available in:
मराठीहिन्दीಕನ್ನಡ